Literature DB >> 11720794

Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient.

Y Takeshima1, H Wada, M Yagi, Y Ishikawa, Y Ishikawa, R Minami, H Nakamura, M Matsuo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11720794     DOI： 10.1016/s0387-7604(01)00326-6

Source DB:  PubMed          Journal:  Brain Dev        ISSN： 0387-7604            Impact factor:   1.961


× No keyword cloud information.
  15 in total

1.  Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.

Authors:  Sue Fletcher; Abbie M Adams; Russell D Johnsen; Kane Greer; Hong M Moulton; Steve D Wilton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

2.  A commentary on a novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy.

Authors:  Yukitoshi Ishikawa
Journal:  J Hum Genet       Date:  2014-07-03       Impact factor: 3.172

Review 3.  Molecular therapeutic strategies targeting Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Louise R Rodino-Klapac; Vinod Malik
Journal:  J Child Neurol       Date:  2010-05-24       Impact factor: 1.987

4.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

Review 5.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

6.  Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy.

Authors:  Laura van Vliet; Christa L de Winter; Judith C T van Deutekom; Gert-Jan B van Ommen; Annemieke Aartsma-Rus
Journal:  BMC Med Genet       Date:  2008-12-01       Impact factor: 2.103

7.  Therapeutic exon skipping for dysferlinopathies?

Authors:  Annemieke Aartsma-Rus; Kavita H K Singh; Ivo F A C Fokkema; Ieke B Ginjaar; Gert-Jan van Ommen; Johan T den Dunnen; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2010-02-10       Impact factor: 4.246

Review 8.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 9.  Progress in therapeutic antisense applications for neuromuscular disorders.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

Review 10.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Authors:  Ryszard Kole; Adrian R Krainer; Sidney Altman
Journal:  Nat Rev Drug Discov       Date:  2012-01-20       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.